BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/11/2022 8:36:01 AM | Browse: 500 | Download: 1340
 |
Received |
|
2021-12-20 12:35 |
|
Peer-Review Started |
|
2021-12-20 12:37 |
|
First Decision by Editorial Office Director |
|
2022-04-08 00:24 |
|
Return for Revision |
|
2022-04-08 00:24 |
|
Revised |
|
2022-04-17 09:30 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-05-30 02:49 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-06-03 21:19 |
|
Articles in Press |
|
2022-06-03 21:19 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-07-03 08:47 |
|
Publish the Manuscript Online |
|
2022-07-11 08:36 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Hematology |
| Manuscript Type |
Case Report |
| Article Title |
Refractory lymphoma treated with chimeric antigen receptor T cells combined with programmed cell death-1 inhibitor: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Cang-Jian Zhang, Jun-Yu Zhang, Lin-Jie Li and Neng-Wen Xu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jun-Yu Zhang, Doctor, Chief Doctor, Department of Hematopathology, Lishui Municipal Central Hospital, No. 289 Kuocang Road, Lishui 323000, Zhejiang Province, China. zhangjunyu815@163.com |
| Key Words |
Refractory diffuse large B-cell lymphoma; Programmed cell death protein-1 inhibitor; Chimeric antigen receptor T cells; Case report |
| Core Tip |
Primary testicular diffuse large B-cell lymphoma (DLBCL) is an uncommon extranodal disease of lymphomas. Refractory DLBCL responds poorly to other lines of chemotherapy, and is associated with short-term survival. Herein, we report one rare case of chimeric antigen receptor T cells (CAR-T) combined with programmed cell-death protein-1 (PD-1) inhibitor to treat refractory DLBCL in a 41-year-old male. Our findings support the potential benefit of CAR-T combined with PD-1 inhibitor therapies in this type of refractory DLBCL. |
| Publish Date |
2022-07-11 08:36 |
| Citation |
Zhang CJ, Zhang JY, Li LJ, Xu NW. Refractory lymphoma treated with chimeric antigen receptor T cells combined with programmed cell death-1 inhibitor: A case report. World J Clin Cases 2022; 10(21): 7502-7508
|
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i21/7502.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i21.7502 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
